BridgeBio Pharma, Inc. (MUN:2CL)
Germany · Delayed Price · Currency is EUR | Market Cap | 13.47B +68.3% |
| Revenue (ttm) | 624.15M +202.4% |
| Net Income | -605.59M |
| EPS | -3.12 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 100 |
| Open | 72.62 |
| Previous Close | 75.53 |
| Day's Range | 69.13 - 72.62 |
| 52-Week Range | 40.12 - 75.53 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 10, 2026 |
About BridgeBio Pharma
BridgeBio Pharma, Inc., a biopharmaceutical company, discovers, develops, and delivers medicines for patients with genetic diseases. The company offers Attruby, a next-generation oral small molecule near-complete TTR stabilizer for the treatment of cardiomyopathy of wild-type or transthyretin-mediated amyloidosis (ATTR-CM); Fosdenopterin, an intravenous formulation of synthetic cyclic pyranopterin monophosphate for the treatment of molybdenum cofactor deficiency under the NULIBRY brand name; and low-dose infigratinib, an oral FGFR1-3 selective ... [Read more]
Financial Performance
In 2025, BridgeBio Pharma's revenue was $502.08 million, an increase of 126.26% compared to the previous year's $221.90 million. Losses were -$724.93 million, 35.3% more than in 2024.
Financial numbers in USD Financial StatementsNews
BridgeBio Pharma doses first patient in ASCEND-ATTR trial
BridgeBio Pharma (BBIO) announced that the first participant has been dosed in ASCEND-ATTR, a Phase 3b/4 study designed to further characterize the long-term effects of acoramidis on the improvement o...
BridgeBio Announces First Participant Dosed in ASCEND-ATTR, a Phase 3b/4 Study Evaluating the Long-Term Effects of Acoramidis on Disease Regression in ATTR-CM
- The ASCEND-ATTR study builds on the Phase 3 ATTRibute-CM CMR substudy results previously shared here, which indicated treatment with acoramidis may improve cardiac structure and function with eviden...
BridgeBio Pharma participates in a conference call with Cantor
Cantor Fitzgerald holds a conference call with management on August 28 at 10 am. Webcast Link
BridgeBio to Present New Acoramidis Data from Open-Label Extension Analyses in ATTR-CM at ESC Congress 2026
PALO ALTO, Calif., Aug. 24, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic condi...
BridgeBio Oncology announces 5M common stock offering for holders
BridgeBio Pharma (BBIO) announced the launch of a secondary public offering of 5M shares of its common stock by the selling stockholder KKR Genetic Disorder. The company is not selling…
BridgeBio Pharma Announces Pricing of Oversubscribed Secondary Offering that Diversifies its Institutional Shareholder Base
- The transaction supports the evolution of the Company's shareholder base toward further high-quality, long-term ownership PALO ALTO, Calif., Aug. 14, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. ...
BridgeBio Pharma Announces Launch of Secondary Offering of Common Stock on Behalf of an Existing Shareholder
PALO ALTO, Calif., Aug. 13, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio”), a commercial-stage, multi-product biopharmaceutical company focused on developing medicines fo...
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
PALO ALTO, Calif., Aug. 11, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic condi...
BridgeBio price target raised to $110 from $95 at TD Cowen
TD Cowen raised the firm’s price target on BridgeBio (BBIO) to $110 from $95 and keeps a Buy rating on the shares. The firm said BridgeBio is at the next…
BridgeBio price target lowered to $97 from $98 at Morgan Stanley
Morgan Stanley analyst Sean Laaman lowered the firm’s price target on BridgeBio (BBIO) to $97 from $98 and keeps an Overweight rating on the shares. Q2 total revenues and Attruby…
BridgeBio price target raised to $102 from $98 at Wells Fargo
Wells Fargo analyst Derek Archila raised the firm’s price target on BridgeBio (BBIO) to $102 from $98 and keeps an Overweight rating on the shares. The firm likes the setup…
BridgeBio price target raised to $115 from $111 at Piper Sandler
Piper Sandler raised the firm’s price target on BridgeBio (BBIO) to $115 from $111 and keeps an Overweight rating on the shares following quarterly results and business update. The quarter…
BridgeBio price target raised to $104 from $101 at BofA
BofA raised the firm’s price target on BridgeBio (BBIO) to $104 from $101 and keeps a Buy rating on the shares after another “strong quarter” from Attruby. However, the “key…
BridgeBio Pharma Earnings Call Transcript: Q2 2026
Q2 saw robust revenue growth, led by Attruby's clinical differentiation and expanding first-line share. Three late-stage programs advanced to regulatory review, with two receiving priority status, and a $1B equity raise strengthened the balance sheet for upcoming launches.
BridgeBio Pharma Earnings release: Q2 2026
BridgeBio Pharma released its Q2 2026 earnings on August 10, 2026, summarizing the period's financial results.
BridgeBio Pharma Quarterly report: Q2 2026
BridgeBio Pharma has published its Q2 2026 quarterly earnings report on August 10, 2026.
BridgeBio Pharma Slides: Corporate presentation
BridgeBio Pharma has posted slides in relation to its latest quarterly earnings report, which was published on August 10, 2026.
BridgeBio to Report Second Quarter 2026 Financial Results and Commercial Updates on August 10, 2026 at 4:30 pm ET
PALO ALTO, Calif., Aug. 03, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic condi...
BridgeBio files to sell 24.63M shares of common stock for holders
17:21 EDT BridgeBio (BBIO) files to sell 24.63M shares of common stock for holders
BridgeBio announces FDA acceptance of encaleret NDA
BridgeBio (BBIO) announced the FDA has accepted for filing its new drug application, or NDA, for encaleret for the treatment of individuals living with autosomal dominant hypocalcemia type 1. The…
BridgeBio Announces FDA Acceptance of NDA for Encaleret for ADH1
- PDUFA target action date of May 8, 2027 - If approved, encaleret will be the first and only approved therapy specifically indicated for individuals living with ADH1 , representing a potential blockb...
BridgeBio price target raised to $93 from $82 at Citi
Citi raised the firm’s price target on BridgeBio (BBIO) to $93 from $82 and keeps a Neutral rating on the shares. The firm adjusted models in the smid-cap biotech group…
BridgeBio price target raised to $120 from $110 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on BridgeBio (BBIO) to $120 from $110 and keeps a Buy rating on the shares. The firm says the company’s acoramidis may benefit…
Acoramidis Associated with First-Ever Early and Sustained Direct Kidney-Protective Effects in ATTR-CM
- Acoramidis initiation was associated with rapid kidney-protective activity as exhibited in a hemodynamically mediated, reversible eGFR dip and a placebo-corrected 15.5% reduction in UACR by Day 28 (...